CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities…

Capricor's stock surged 370% after reported positive DMD trial results (Dec 2025), then dropped 64% when the FDA exposed undisclosed statistical analysis plan modifications. Data governance and pre-trial transparency are non-negotiable for regulated biotech and AI—compliance lapses destroy shareholder value.